Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2019.CA Cancer J Clin. 2019; 69: 7-34
- Cancer treatment and survivorship statistics, 2014.CA Cancer J Clin. 2014; 64: 252-271
- CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015.Neuro Oncol. 2018; 20: iv1-iv86
- Outcome and prognostic factors of radiation therapy for medulloblastoma.Int J Radiat Oncol Biol Phys. 2011; 81: e7-e13
- Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.N Engl J Med. 2005; 352: 978-986
- Prognostic factors and secondary malignancies in childhood medulloblastoma.J Pediatr Hematol Oncol. 2001; 23: 431-436
- Intertumoral heterogeneity within medulloblastoma subgroups.Cancer Cell. 2017; 31: 737-754.e6
- Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.Lancet Oncol. 2017; 18: 958-971
- Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.Lancet Oncol. 2016; 17: 484-495
- Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study.Neuro Oncol. 2017; 19: 1673-1682
- Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.J Clin Oncol. 2006; 24: 4202-4208
- Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.Neuro Oncol. 2013; 15: 97-103
- Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.J Clin Oncol. 2012; 30: 2648-2653
- Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.Lancet Oncol. 2006; 7: 813-820
- Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.J Clin Oncol. 2009; 27: 566-571
- The UK experience of a treatment strategy for pediatric metastatic medulloblastoma comprising intensive induction chemotherapy, hyperfractionated accelerated radiotherapy and response directed high dose myeloablative chemotherapy or maintenance chemotherapy (Milan strategy).Pediatr Blood Cancer. 2015; 62: 2132-2139
- Results of COG ACNS0331: a phase III trial of involved-field radiotherapy (IFRT) and low dose craniospinal irradiation (LD-CSI) with chemotherapy in average-risk medulloblastoma: a report from the Children's Oncology Group.Int J Radiat Oncol Biol Phys. 2016; 96: 937-938
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.Acta Neuropathol. 2012; 123: 473-484
- Attainment of functional and social independence in adult survivors of pediatric CNS tumors: a report from the St Jude Lifetime Cohort Study.J Clin Oncol. 2018; 36: 2762-2769
- Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the childhood cancer survivor study.J Clin Oncol. 2019; 37: 731-740
- Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.Lancet Oncol. 2016; 17: 287-298
- Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study.J Clin Oncol. 2019; 37: 1090-1101
- Medulloblastoma comprises four distinct molecular variants.J Clin Oncol. 2011; 29: 1408-1414
- Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis.J Clin Oncol. 2010; 28: 4961-4968
- A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas.J Neurosurg Pediatr. 2013; 11: 673-681
- Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91.Int J Radiat Oncol Biol Phys. 2000; 46: 287-295
- Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.J Neurooncol. 2013; 115: 411-419
- Outcomes following proton therapy for pediatric ependymoma.Acta Oncol. 2018; 57: 644-648
- Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study.Lancet Oncol. 2009; 10: 258-266
- Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients.Neuro Oncol. 2013; 15: 1552-1559
- Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.Neuro Oncol. 2016; 18: 1451-1460
- Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma.J Clin Oncol. 2019; 37: 974-983
- Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy.Acta Oncol. 2014; 53: 1298-1304
- Protons, the brainstem, and toxicity: ingredients for an emerging dialectic.Acta Oncol. 2014; 53: 1279-1282
- Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.J Clin Oncol. 2004; 22: 2877-2884
- Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.J Clin Oncol. 2005; 23: 1491-1499
- Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996-2006.Cancer. 2010; 116: 5725-5732
- Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.J Clin Oncol. 2009; 27: 385-389
- AT-09TREATMENT of atypical teratoid rhabdoid tumors (ATRT) of the central nervous system with surgery, intensive chemotherapy, and 3-D conformal radiation (ACNS0333).A report from the Children's Oncology Group. 2016; Vol 18: 1-21
- Pediatric central nervous system germ cell tumors: a review.Oncologist. 2008; 13: 690-699
- Bifocal intracranial tumors of nongerminomatous germ cell etiology: diagnostic and therapeutic implications.Neuro Oncol. 2013; 15: 955-960
- Radiation therapy for intracranial germ cell tumors.Int J Radiat Oncol Biol Phys. 2003; 56: 511-518
- Radiotherapy of localised intracranial germinoma: time to sever historical ties?.Lancet Oncol. 2005; 6: 509-519
- Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.J Clin Oncol. 1999; 17: 933-940
- Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation.J Neurooncol. 2016; 127: 173-180
- Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children's Oncology Group Study.J Clin Oncol. 2015; 33: 2464-2471
- Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes.Int J Radiat Oncol Biol Phys. 2011; 79: 121-129
- Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group.Neurosurgery. 2011; 68 ([discussion: 1554–5]): 1548-1554
- Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.J Clin Oncol. 2012; 30: 2641-2647
- Phase II trial of conformal radiation therapy for pediatric low-grade glioma.J Clin Oncol. 2009; 27: 3598-3604
- Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma.Cancer. 2013; 119: 2654-2659
- Conformal radiation therapy for pediatric patients with low-grade glioma: results from the Children's Oncology Group Phase 2 Study ACNS0221.Int J Radiat Oncol Biol Phys. 2019; 103: 861-868
- Outcomes following proton therapy for pediatric low-grade glioma.Int J Radiat Oncol Biol Phys. 2019; 104: 149-156
- Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas.Int J Radiat Oncol Biol Phys. 2014; 89: 1060-1068
- Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.J Clin Oncol. 2009; 27: 3391-3397
- PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.J Clin Oncol. 2012; 30: 1670-1677
- Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.J Clin Oncol. 2010; 28: 2151-2158
- Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group.J Clin Oncol. 2018; 36: 2770-2777
- Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): a report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).J Clin Oncol. 2018; 36: LBA2
- Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children's Oncology Group.J Clin Oncol. 2016; 34: 117-122
- Local control for intermediate-risk rhabdomyosarcoma: results from d9803 according to histology, group, site, and size: a report from the Children's Oncology Group.Int J Radiat Oncol Biol Phys. 2015; 93: 1071-1076
- 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.Pediatr Blood Cancer. 2017; 64: 1-11
- Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.J Clin Oncol. 2014; 32: 3762-3770
- The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.J Clin Oncol. 2009; 27: 289-297
- Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.N Engl J Med. 2010; 363: 1324-1334
- Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.Int J Radiat Oncol Biol Phys. 2003; 56: 28-39
- Change in radiation therapy to the primary tumor site in patients with high-risk neuroblastoma.2019
- The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study.Cancer. 1981; 47: 2302-2311
- Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study.Cancer. 1989; 64: 349-360
- Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.J Clin Oncol. 2005; 23: 7312-7321
- Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children's Oncology Group.J Clin Oncol. 2016; 34: 3189-3194
- Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children's Oncology Group AREN0533 Study.J Clin Oncol. 2018; 36: 1564-1570
- Results of the first prospective multi-institutional treatment study in children with bilateral Wilms tumor (AREN0534): a report from the Children's Oncology Group.Ann Surg. 2017; 266: 470-478
- Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.J Clin Oncol. 2012; 30: 4148-4154
- Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.J Clin Oncol. 2006; 24: 3838-3843
- Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group.Cancer. 2015; 121: 467-475
- Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials.Int J Radiat Oncol Biol Phys. 2003; 55: 168-177
- Molecular subgroups of medulloblastoma: the current consensus.Acta Neuropathol. 2012; 123: 465-472
- Medulloblastoma.Nat Rev Dis Primers. 2019; 5: 11
Article info
Publication history
Published online: October 30, 2019
Footnotes
Conflicts of Interest: None.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
